How do I tell whether this is the drug or a stomach bug?

Often you cannot, and it does not change what happens next. Gastrointestinal reactions on this class cluster at initiation and after each increase, so a clinician will ask how recently your dose changed. Either way the labelled danger runs through fluid loss, so the fluids and the warning signs listed on this page are the same answer to both versions of the question.

I feel better today, but yesterday I barely passed any urine. Too late to mention it?

No, and it is worth mentioning. Labelling directs monitoring of renal function in patients reporting reactions severe enough to cause dehydration, so asking for bloods after an episode like that is an ordinary request rather than a fuss. Feeling better is not the same thing as filtration having recovered, and a test is what tells the two apart.

It is diarrhoea only, no vomiting. Does the warning still apply?

Yes. The labelled sequence names nausea, vomiting or diarrhoea, and diarrhoea alone strips water and salts faster than plain water puts them back. Keeping food down is not the test. The signs that warrant a same-day call are unchanged by which end of the illness you are dealing with.

GLP-1 Sick Days: Vomiting, Diarrhoea and When to Get Help

What this page establishes

Most reported postmarketing acute kidney injury events on GLP-1 receptor agonists followed GI reactions causing dehydration.
FDA has required labelling changes adding or revising subsections for Acute Pancreatitis and Severe Gastrointestinal Adverse Reactions across the class.
Labelling advises monitoring renal function in patients with adverse reactions that could cause severe dehydration, especially at initiation and escalation.
ADA guidance directs reassessment of insulin and sulfonylurea doses when a GLP-1 is present, which becomes acutely relevant when food intake stops.

Quick answers

How do I tell whether this is the drug or a stomach bug?
Often you cannot, and it does not change what happens next. Gastrointestinal reactions on this class cluster at initiation and after each increase, so a clinician will ask how recently your dose changed.
Read the full answer
Either way the labelled danger runs through fluid loss, so the fluids and the warning signs listed on this page are the same answer to both versions of the question.
I feel better today, but yesterday I barely passed any urine. Too late to mention it?
No, and it is worth mentioning. Labelling directs monitoring of renal function in patients reporting reactions severe enough to cause dehydration, so asking for bloods after an episode like that is an ordinary request rather than a fuss.
Read the full answer
Feeling better is not the same thing as filtration having recovered, and a test is what tells the two apart.
It is diarrhoea only, no vomiting. Does the warning still apply?
Yes. The labelled sequence names nausea, vomiting or diarrhoea, and diarrhoea alone strips water and salts faster than plain water puts them back.
Read the full answer
Keeping food down is not the test. The signs that warrant a same-day call are unchanged by which end of the illness you are dealing with.

If you are on a GLP-1 and currently vomiting or have diarrhoea, the thing to know is that dehydration is the risk that matters, not the sickness itself. FDA labelling across this drug class warns of serious kidney injury resulting from dehydration, in some cases requiring haemodialysis, and states that most reported cases followed nausea, vomiting or diarrhoea. That is a short chain and it can be interrupted at the fluid stage. The question everybody asks, whether to take the next dose, is a prescriber decision, and this page will not answer it for you because it cannot. What it will do is tell you what the labels warn about, what to watch for, and the specific signs that mean stop reading and call someone.

Signs that mean contact someone today

These are the points at which an unpleasant illness becomes something needing assessment. You do not need several of them. One is enough.

You cannot keep fluids down for more than a few hours
Your urine output has dropped, your urine is very dark, or you have not passed urine
Severe abdominal pain, particularly pain radiating through to your back
Dizziness on standing, confusion, or marked weakness
Blood in vomit or stool
Low blood glucose while unable to eat, if you take insulin or a sulfonylurea
Vomiting or diarrhoea continuing beyond about 24 hours

Severe abdominal pain radiating to the back is not a stomach bug FDA has required labelling across this class to add or revise subsections covering acute pancreatitis and severe gastrointestinal adverse reactions. Pain of that character during a GI illness needs urgent assessment rather than waiting it out at home.

The chain the labels warn about

Ozempic prescribing information, and equivalent labelling across the class, describes postmarketing reports of acute kidney injury and worsening of chronic renal failure, sometimes requiring haemodialysis. The label states that the majority of reported events occurred in patients who had experienced nausea, vomiting or diarrhoea leading to dehydration.

So the pathway is explicit and it has three steps. Gastrointestinal symptoms, then loss of circulating volume, then reduced kidney perfusion. The label also advises monitoring renal function in patients reporting severe adverse gastrointestinal reactions, particularly at initiation and during dose escalation, which is when those reactions cluster.

The useful thing about a three-step chain is that the middle step is the one you can act on. Kidney injury from volume depletion is pre-renal, which means it is reversible if volume is restored early and damaging if it is not.

Why the starting point is lower on this drug class

Someone on a GLP-1 begins an illness with less margin than they would otherwise have. Food volume is already reduced, and a meaningful fraction of daily water intake normally comes from food. Early satiety limits how much can be drunk comfortably in one go, so replacing losses takes more deliberate effort. Delayed gastric emptying means fluid can sit rather than being absorbed at the rate you expect.

Add an illness on top of that and the drop in circulating volume happens from a lower baseline and faster. This is the specific reason a stomach bug deserves more attention on this drug than it did before you started it.

Should you take the next dose?

This is a prescriber decision. Not a hedge, an accurate description of who has the information needed to answer it. The answer depends on which drug you take, what dose you are on, whether you are mid-titration, how long the illness has lasted, and what else you take.

What you can do is make the call easy for them. Have ready: the drug name, the current dose, the date of your last injection, how long you have been unwell, what you have managed to keep down, and roughly when you last passed urine.

Most prescribing services have a route for this that is faster than a routine appointment. Use it. Skipping a dose without telling anyone, or taking one while vomiting because you did not want to bother anybody, are both worse than a five-minute phone call.

There is no published GLP-1 sick-day rule set Insulin and SGLT2 inhibitors have established, published sick-day rules. This drug class does not have an equivalent set. What anchors the advice is the labelling warning about dehydration and kidney injury, plus your prescriber's judgement about your situation. Anyone presenting a definitive GLP-1 sick-day protocol is going beyond what has been published.

Fluids when you cannot eat

Small volumes taken often generally go down better than large ones, which is standard advice for any vomiting illness and applies with more force when gastric emptying is already slowed. Oral rehydration solutions replace electrolytes as well as water, which plain water does not, and diarrhoea in particular costs both.

Getting fluid in is the part of this you have direct control over. If small sips are not staying down at all over several hours, that has crossed from something to manage at home into something to phone about.

If you have type 2 diabetes

Illness creates a second, opposite problem for you. Food intake stops while insulin or a sulfonylurea keeps working, and the risk shifts toward hypoglycaemia.

ADA Standards of Care 2026 already direct that sulfonylureas be discontinued or reduced and insulin doses adjusted when a GLP-1 receptor agonist is added, with examples such as reducing bolus insulin by 10% to 20% and basal by around 10% where HbA1c is under 7.5%. Those adjustments were made for normal eating. An illness that stops eating altogether changes the arithmetic again.

The right time to sort this out is before you are unwell. An illness plan agreed with your diabetes team, written down, covering what to do about each medication and when to call, is worth having in place while you are well enough to think clearly.

Restarting afterwards

If you missed one or more doses, resuming at your previous dose may not be right. Tolerance to this drug class fades with a gap, and the gastric-emptying effect returns at full strength when you restart, which is the same reason side effects cluster at initiation.

Ask your prescriber whether you resume where you left off or re-titrate. The answer depends on how long the gap was, and it is a short question with a clear answer, so it is worth asking rather than guessing.

A note if food restriction is difficult for you

An illness that removes appetite entirely can be quietly welcome to someone with a history of restrictive eating, and the recovery period, when eating has to start again deliberately, can be genuinely hard. If that describes you, this is worth naming to your clinician rather than managing alone. Eating disorder support services exist for exactly this, and using them is not an overreaction.

Not medical advice

This page describes what FDA labelling for this drug class warns about and what published guidance says. It is general educational information, not advice about your illness or your dose. If you are unwell right now and any of the signs listed near the top of this page apply, contact a clinician or emergency service rather than continuing to read.

The evidence, one row per claim

Claim	Tier	Source
Most reported postmarketing acute kidney injury events on GLP-1 receptor agonists followed GI reactions causing dehydration.	established	OZEMPIC US Prescribing Information, FDA
FDA has required labelling changes adding or revising subsections for Acute Pancreatitis and Severe Gastrointestinal Adverse Reactions across the class.	established	OZEMPIC US Prescribing Information, FDA
Labelling advises monitoring renal function in patients with adverse reactions that could cause severe dehydration, especially at initiation and escalation.	established	OZEMPIC US Prescribing Information, FDA
ADA guidance directs reassessment of insulin and sulfonylurea doses when a GLP-1 is present, which becomes acutely relevant when food intake stops.	established	ADA Standards of Care in Diabetes 2026, Section 9
There is no published GLP-1-specific sick-day rule set equivalent to the established sick-day rules for insulin or SGLT2 inhibitors.	anecdotal	unsourced

Sources

Where this comes from

Researched and edited by Thomas Prommer — biohacker, performance athlete, data enthusiast and health coach.

Every number on this page traces to a named source. There are 5 sourced claims below the fold, each with the document it came from.

Sources consulted: OZEMPIC US Prescribing Information, ADA Standards of Care in Diabetes 2026, unsourced.

Not clinically reviewed. This page was researched and written against primary regulatory and trial sources, and no clinician has checked it.

Sources last read 2026-08-23.

Keep reading

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.